Search Results
Your search for ,ShE matches 5598 pages
Showing 1051 - 1100Study Finds Preoperative MRI Does Not Significantly Impact Margin Status in Patients With Breast Cancer
The use of preoperative magnetic resonance imaging (MRI) did not significantly reduce positive margins after breast-conserving surgery, according to data presented during a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Although MRI has been shown to detect...
Expert Point of View: Tina Cascone, MD, PhD
Discussant of the Neotorch study abstract, Tina Cascone, MD, PhD, of the Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, commended the authors for completing the initial analysis of the phase III randomized Neotorch trial, which...
Pembrolizumab Added to Chemotherapy Improves Survival in Advanced Cervical Cancer Regardless of PD-L1 Expression
The addition of pembrolizumab to chemotherapy with or without bevacizumab led to improved overall survival and progression-free survival in women with persistent, recurrent, or metastatic cervical cancer in the final protocol-specified overall survival analysis of the KEYNOTE-826 trial presented at ...
NCCN Addresses Ongoing Chemotherapy Shortages as New Survey Suggests More than 90% of Cancer Centers May Be Impacted
Results of a new survey from the National Comprehensive Cancer Network (NCCN) have shed light on the widespread impact of the current carboplatin and cisplatin shortages. In a separate statement, the NCCN called on the whole oncology community to work together on solutions. Background Carboplatin...
Involving All of Society to End Cancer as We Know It
This has been a year of firsts and seconds for Monica M. Bertagnolli, MD, FACS, FASCO. This past October, Dr. Bertagnolli became the 16th Director of the National Cancer Institute (NCI), the first woman and the first clinical trials cooperative group chair to hold that position. Then, 2 months...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal cancer,...
Stopping Immunotherapy After 2 Years vs Continuing Treatment May Yield Similar Survival Outcomes in Patients With Advanced NSCLC
Patients with advanced non–small cell lung cancer (NSCLC) may be able to stop receiving immunotherapy at 2 years as long as their cancer hasn’t progressed, according to new findings presented by Sun et al at the 2023 ASCO Annual Meeting (Abstract 9101) and simultaneously published in JAMA Oncology. ...
Race and Ethnicity May Affect 21-Gene Recurrence Score in Patients With Estrogen Receptor–Positive Breast Cancer
Investigators have found that race and ethnicity may affect the 21-gene recurrence score in patients with early-stage, estrogen receptor–positive breast cancer, according to new findings presented by Gill et al at the 2023 ASCO Annual Meeting (Abstract 511). Background The 21-gene recurrence...
Exercise May Strengthen Immune System in Patients With Multiple Myeloma
Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....
Chemotherapy-Induced Peripheral Neuropathy May Be More Severe With Paclitaxel Than With Docetaxel
Researchers have found that patients who have breast cancer who undergo treatment with taxanes show a pattern of clinically meaningful, persistent sensory and motor symptoms associated with chemotherapy-induced peripheral neuropathy, according to new findings presented by Trivedi et al at the 2023...
Changes in RECIST Tumor Measures Correlate Linearly With Survival in Patients Treated With Checkpoint Inhibitors
The Response Evaluation Criteria in Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories—complete response, partial response, stable disease, or progressive disease—based on the percent of...
Impact of Changing Opioid Prescription Landscape for Patients With Cancer
Despite the common use of opioids in clinical settings, new and persistent opioid prescriptions have declined among patients both with and without cancer, according to new findings presented by Baum et al at the 2023 ASCO Annual Meeting (Abstract 1592). However, the declines in opioid use among...
Early Cessation of Neoadjuvant Chemotherapy May Lead to Worse Outcomes in Patients With Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to cystectomy may have an increased risk of cancer recurrence and worse survival outcomes, according to the findings of a retrospective study presented by Chakraborty et al at the 2023 ASCO Annual ...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
Daughter of Immigrants Who Fled the Pogroms, She Followed a Love of Science Into a Noted Career in Cancer Pathology
In the era of genomics and precision medicine, the role of pathology in diagnosis and cancer management is rapidly evolving. For the past 50 years, from her office at the Center for Cancer Research, National Cancer Institute (NCI), pathologist Elaine S. Jaffe, MD, has been at the forefront of that...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
An Oncology Leader Whose Immigrant Parents Taught Him by Example About Life and Service to Humanity
According to Sunil R. Hingorani, MD, PhD, his parents figured heavily on who he became as a person and on his career choices, which ultimately led to his current position as Director of the Pancreatic Cancer Center of Excellence at the University of Nebraska College of Medicine, Omaha. “My father...
Involvement in SWOG and JCO Leads to a Fulfilling Career as a Leader in Oncology
Jonathan W. Friedberg, MD, MMSc, Director of the James P. Wilmot Cancer Institute, grew up in a suburb of Milwaukee. While his school friends were attending camp, he spent his summers working on the family farm. “Perhaps the hardest work I’ve ever done was haying on a hot, humid night in July,...
An Oncologist From Guam Devotes His Career to the Care of Pelvic Cancers and the Sexual Health of All Cancer Survivors
Don S. Dizon, MD, FACP, FASCO, Director of Pelvic Malignancies Program at Lifespan Cancer Institute and Director of Medical Oncology at Rhode Island Hospital was born and reared in Guam. He also is Professor of Medicine and Professor of Surgery at Brown University, Providence, Rhode Island. “I am...
The Second-Generation Son of Greek Immigrants, the First to Go to College, Becomes a Leader in Sarcoma Research and Treatment
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Professor of Medicine and Co-Director of the Ludwig Center at Harvard, was born in Hyde Park, a town along the Hudson River in New York. When Dr. Demetri was growing up there, it was known for three...
Patients Who Practice Qigong May Be Able to Improve Their Cancer-Related Fatigue
Researchers have found that patients with cancer-related fatigue who practiced qigong may have demonstrated clinically significant improvements in their fatigue burden after 10 weeks, according to a new study published by Zimmerman et al in Integrative Cancer Therapies. The findings revealed that...
Mourned and Missed
The respected members of the oncology community listed here are among some of those who passed away in 2022–2023. The ASCO Post remembers them, their lives, and their contributions to cancer research and treatment. Robert J. Gillies, PhD Moffitt Cancer Center and the global research community lost ...
A Leader in Oncology From Humble Beginnings Never Forgets Life Lessons Learned Along the Way
In December 2019, Robert A. Winn, MD, became the second Black physician to lead a National Cancer Institute (NCI)-designated comprehensive cancer center when he took the helm of the Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Winn’s basic science research, which has been...
A Love of Immunology Leads to a Notable Career in Dermatology, With a Focus on Melanoma Research and Treatment
Caroline Robert, MD, PhD, Head of the Dermatology Unit at Gustave Roussy and Co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, was born and reared in Paris. “I didn’t have a vocation for medicine when I was a kid; I wanted to be an archeologist. I’m not from a medical...
Inspired by an Uncle Who Was a Compassionate Family Doctor, This Nonagenarian Continues a Renowned Career in Hematology
Today is the era of the multidisciplinary oncology care approach, cancer staging facilitates precision in documenting disease extent, all of which improved the quality of patient care. However, in the United States, the Rai staging system is still the most commonly used clinical staging system for...
From a Small Town in North Carolina, a Young Girl Finds Her Calling in Battling Inequity in Cancer Care
Manali Patel, MD, MPH, Associate Professor of Medicine (Oncology) at Stanford University, grew up in Shelby, a small town in the textile and farming community of Western North Carolina, among mill workers and other blue-collar laborers. The daughter of Indian immigrants, Dr. Patel’s early life was...
A Free-Spirited Childhood on a Dairy Farm, Where Books and Science Experiments Were Encouraged
Susan K. Parsons, MD, MRP, Professor of Medicine and Pediatrics at Tufts University School of Medicine and Founding Director of the Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Disorders at Tufts Medical Center, grew up on a working dairy farm in Sharon Springs,...
Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays
Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of ...
Telephone-Based Weight Loss Intervention for Patients With Breast Cancer and Overweight/Obesity
A randomized study by Jennifer A. Ligibel, MD, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School, evaluating the impact of a telephone-based weight loss intervention in...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award...
Making the Art of Oncology and Cancer Care Central to Her Presidential Term
Lynn M. Schuchter, MD, FASCO, has said that volunteering and working with ASCO over many years has been the highlight of her career. She served on the ASCO Board of Directors from 2009 to 2012 and on several ASCO committees, including terms as Chair of the Annual Meeting Scientific Program...
Northwell Launches Cancer Care Direct, Pairing Nurse Navigators With Patients Through Spectrum of Care
Knowing the health-care system is complex and often creates anxiety for patients newly diagnosed with cancer, the Northwell Health Cancer Institute has launched Cancer Care Direct, a comprehensive program to connect patients with clinical registered nurse navigators who can provide expert guidance...
Surviving, but Not Always Thriving, After Cancer
The improvement in cancer survival rates since President Richard M. Nixon signed the National Cancer Act of 1971 into law is staggering. The legislation further committed the United States to greater investments in cancer-focused research to drive down the rates of cancer diagnoses, boost patient...
Playing a Doctor in a School Play Sparked an Early Desire to Become a Real Doctor for Sibylle Loibl, MD, PhD
For this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sibylle Loibl, MD, PhD, Chair of the German Breast Group (GBG) and Chief Executive Officer of the GBG Forschungs GmbH. Professor Loibl, Associate Professor of Obstetrics and Gynecology ...
Expert Point of View: Elizabeth A. Morris, MD
Elizabeth A. Morris, MD, Professor and Chair of the Department of Radiology at the University of California Davis, Sacramento, told The ASCO Post that the study by Berger et al addresses an important question. “This is a topic I am kind of passionate about—it addresses the ordering of mammograms...
Surveillance Mammography Rates After Breast Cancer Treatment Remain High, Irrespective of Life Expectancy
Is regular surveillance with mammography important in older patients with breast cancer and a shortened life expectancy? A study of 44,475 patients with breast cancer found the practice—which may yield more harms than benefits—to be common. This study is unique in that it examined surveillance...
Expert Point of View: Carol Aghajanian, MD
Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York, commented on the final analysis of NOVA for The ASCO Post. She highlighted the difficulty in truly measuring overall survival in recurrent ovarian cancer. Dr. Aghajanian also ...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival
Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
Expert Point of View: Amanda Nickles Fader, MD
Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...
Expert Point of View: Kathleen Moore, MD, MS
Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
Genetic Sequencing May Identify Cancers Often Missed by Traditional Screening Guidelines
Whole-exome sequencing of a large database identified carriers of mutations associated with hereditary cancer syndromes (ie, hereditary breast and ovarian cancers and Lynch syndrome). What was surprising was that among those carriers, about 40% did not satisfy the existing National Comprehensive...
FDA Approves Avapritinib for Indolent Systemic Mastocytosis
On May 22, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis. Avapritinib is the first and only approved therapy for indolent systemic mastocytosis. Systemic mastocytosis is a rare ...
Expert Point of View: Kenneth C. Anderson, MD
Kenneth C. Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute, and Kraft Family Professor of Medicine, Harvard Medical School, was upbeat about the REGN5459 study and the field of melanoma studies in...
Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial
The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...
Organizations Team Up to Improve Cancer Care in Rural Appalachia
The Appalachian Community Cancer Alliance (ACCA) has launched a lung cancer screening initiative to improve cancer care in rural Appalachia. Home to nearly 26 million people, the Appalachian region includes all of West Virginia and parts of 12 other states, and it has a 10% higher cancer mortality...
Study Analyzes Relationship Between Cancer Survivors’ Tobacco Use, Symptom Burden, and Motivation to Quit Smoking
Investigators have found that current smoking and vaping may be associated with a higher burden of symptoms among adult cancer survivors but that these symptoms may not have had an impact on the desire to quit smoking. The new study was published by Price et al in Cancer. Background Continued...
Expert Point of View: Sarah Blair, MD
Sarah Blair, MD, Professor and Vice Chair of the Department of Surgery at UC San Diego Health in California, offered her thoughts on the findings from these two studies. She first pointed to the growing body of data showing how nutrition and exercise programs can improve aerobic fitness, quality of ...
